Authors
Xinqiang Zhu, Beibei Ge, Siwei Shan, Linchun Wen
Published in
Cancer management and research. Volume 18. Pages 618911. Epub Aug 06, 2026.
Abstract
Colorectal cancer (CRC) remains a leading cause of cancer mortality. While genetic drivers are well-characterized, epigenetic alterations-particularly DNA methylation-are increasingly recognized as critical contributors. The vitamin B12 transporter Transcobalamin I (TCN1) has recently emerged as an epigenetically regulated gene with context-dependent oncogenic functions.
This review synthesized current evidence positioning TCN1 at the intersection of metabolic regulation and oncogenic signaling. We critically evaluated TCN1's consistent overexpression in CRC, its regulation by promoter methylation, and its functional interactions with the Wnt/β-catenin and Notch pathways via Integrin Beta 4 (ITGB4). Notably, we identified and explored the "TCN1 paradox"-the tissue-specific prognostic disparities observed across gastrointestinal cancers-and proposed mechanistic hypotheses to explain this divergence. We also assessed TCN1's clinical potential as a liquid biopsy biomarker, discussing analytical challenges and benchmarking requirements against established tests like SEPT9 methylation.
TCN1 represents a promising multi-functional biomarker in CRC, linking one-carbon metabolism to tumor progression. However, significant knowledge gaps remain regarding its precise molecular mechanisms. We outline a translational roadmap prioritizing in vivo validation, prospective clinical cohorts, and therapeutic vulnerability screening to determine whether TCN1 can transition from a biological player to a clinical tool.
PMID:
42577958
Bibliographic data and abstract were imported from PubMed on 13 Oct 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 5
- Comments 0